Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 11/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19743343 | 0.86 | HPGD (0.37) | HPGDTSHRCNR2HTTSMN1; SMN2 | |
| SCHEMBL19744039 | 0.79 | HPGD (0.40) | HPGDTSHRCNR2HTTSMN1; SMN2 | |
| SCHEMBL14911524 | 0.79 | HTT (0.51) | TSHRCNR2HTTSMN1; SMN2LMNA | |
| SCHEMBL14911407 | 0.77 | KMT2A (0.51) | HPGDCNR2SMN1; SMN2RAD51KMT2A | |
| SCHEMBL14911499 | 0.69 | PDE8B (0.44) | HPGDCNR2RAD51 | |
| SCHEMBL20968378 | 0.68 | TSHR (0.42) | HPGDTSHRCNR2RAD51LMNA | |
| SCHEMBL17731791 | 0.67 | CNR2 (0.43) | CNR2 | |
| SCHEMBL19743667 | 0.66 | CNR2 (0.44) | CNR2 | |
| SCHEMBL19743579 | 0.66 | CNR2 (0.49) | HPGDTSHRCNR2RAD51KMT2A | |
| SCHEMBL19743706 | 0.64 | HPGD (0.40) | HPGDTSHRCNR2HTTRAD51 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10457684-B2 | [1,2,3]triazolo[4,5-d]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190127383-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127383-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | TYMS, TYMP, TBXA2R | HPGD 1645/4885TSHR 838/4885CNR2 167/4885 |
| US-10457684-B2 | [1,2,3]triazolo[4,5-d]pyrimidine derivatives | TYMS, DPYD, TYMP | HPGD 1044/4885TSHR 656/4885CNR2 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.